These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 6819173

  • 1. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK, Hanwell MA, Satchell PM, Turtle JR.
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [Abstract] [Full Text] [Related]

  • 2. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y, Fujimori S, Okada K.
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [Abstract] [Full Text] [Related]

  • 3. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR, Hawthorne JN, Tomlinson DR.
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE, Plurad SB, Sherman WR, Williamson JR, Tilton RG.
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [Abstract] [Full Text] [Related]

  • 8. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH, Tomlinson DR.
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H.
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, Greene DA.
    N Engl J Med; 1988 Sep 01; 319(9):548-55. PubMed ID: 3136331
    [Abstract] [Full Text] [Related]

  • 13. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG, O'Brien IA, Morgan MH, Corrall RJ.
    Diabetologia; 1984 Jun 01; 26(6):445-8. PubMed ID: 6432615
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, Terashima H, Morimura T, Sakamoto N.
    Diabetologia; 1985 Mar 01; 28(3):176-80. PubMed ID: 3922829
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA, Lattimer SA.
    Am J Med; 1985 Nov 15; 79(5A):13-7. PubMed ID: 3000175
    [Abstract] [Full Text] [Related]

  • 20. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M.
    Diabetologia; 1983 Apr 15; 24(4):290-2. PubMed ID: 6407887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.